Trial Information
Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial
Inclusion Criteria:
- completely resected pathological stage IB or II NSCLC
- adequate haematological, renal and liver function and condition
Exclusion Criteria:
- previous chemo or radiotherapy for NSCLC
- bronchoalveolar cell subtype
- second active primary malignancy or serious concomitant medical disease
- difficulties with adequate follow-up
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Success of delivery treatment; data collected during chemotherapy treatment
Principal Investigator
Paul R. Germonpre, MD PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Thoracic Oncology Group Antwerp
Authority:
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Study ID:
TOGA 0501
NCT ID:
NCT00434668
Start Date:
December 2005
Completion Date:
November 2010
Related Keywords:
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- NSCLC
- Adjuvant chemotherapy for completely resected NSCLC
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
